Literature DB >> 23876803

The mucin Muc2 limits pathogen burdens and epithelial barrier dysfunction during Salmonella enterica serovar Typhimurium colitis.

Maryam Zarepour1, Kirandeep Bhullar, Marinieve Montero, Caixia Ma, Tina Huang, Anna Velcich, Lijun Xia, Bruce A Vallance.   

Abstract

Salmonella enterica serovar Typhimurium is a model organism used to explore the virulence strategies underlying Salmonella pathogenesis. Although intestinal mucus is the first line of defense in the intestine, its role in protection against Salmonella is still unclear. The intestinal mucus layer is composed primarily of the Muc2 mucin, a heavily O-glycosylated glycoprotein. The core 3-derived O-glycans of Muc2 are synthesized by core 3 β1,3-N-acetylglucosaminyltransferase (C3GnT). Mice lacking these glycans still produce Muc2 but display a thinner intestinal mucus barrier. We began our investigations by comparing Salmonella-induced colitis and mucus dynamics in Muc2-deficient (Muc2(-/-)) mice, C3GnT(-/-) mice, and wild-type C57BL/6 (WT) mice. Salmonella infection led to increases in luminal Muc2 secretion in WT and C3GnT(-/-) mice. When Muc2(-/-) mice were infected with Salmonella, they showed dramatic susceptibility to infection, carrying significantly higher cecal and liver pathogen burdens, and developing significantly higher barrier disruption and higher mortality rates, than WT mice. We found that the exaggerated barrier disruption in infected Muc2(-/-) mice was invA dependent. We also tested the susceptibility of C3GnT(-/-) mice and found that they carried pathogen burdens similar to those of WT mice but developed exaggerated barrier disruption. Moreover, we found that Muc2(-/-) mice were impaired in intestinal alkaline phosphatase (IAP) expression and lipopolysaccharide (LPS) detoxification activity in their ceca, potentially explaining their high mortality rates during infection. Our data suggest that the intestinal mucus layer (Muc2) and core 3 O-glycosylation play critical roles in controlling Salmonella intestinal burdens and intestinal epithelial barrier function, respectively.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23876803      PMCID: PMC3811786          DOI: 10.1128/IAI.00854-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

Review 1.  Salmonella: a model for bacterial pathogenesis.

Authors:  M E Ohl; S I Miller
Journal:  Annu Rev Med       Date:  2001       Impact factor: 13.739

2.  Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide.

Authors:  Hafida Bentala; Willem R Verweij; Ali Huizinga-Van der Vlag; Annemiek M van Loenen-Weemaes; Dirk K F Meijer; Klaas Poelstra
Journal:  Shock       Date:  2002-12       Impact factor: 3.454

Review 3.  Animal models of Salmonella infections: enteritis versus typhoid fever.

Authors:  R L Santos; S Zhang; R M Tsolis; R A Kingsley; L G Adams; A J Bäumler
Journal:  Microbes Infect       Date:  2001 Nov-Dec       Impact factor: 2.700

4.  Molecular cloning and characterization of a novel UDP-GlcNAc:GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase (beta 3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans.

Authors:  Toshie Iwai; Niro Inaba; Andreas Naundorf; Yan Zhang; Masanori Gotoh; Hiroko Iwasaki; Takashi Kudo; Akira Togayachi; Yasuko Ishizuka; Hiroshi Nakanishi; Hisashi Narimatsu
Journal:  J Biol Chem       Date:  2002-01-30       Impact factor: 5.157

5.  Muc1 mucins on the cell surface are adhesion sites for Pseudomonas aeruginosa.

Authors:  E P Lillehoj; S W Hyun; B T Kim; X G Zhang; D I Lee; S Rowland; K C Kim
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-01       Impact factor: 5.464

6.  Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host.

Authors:  Manja Barthel; Siegfried Hapfelmeier; Leticia Quintanilla-Martínez; Marcus Kremer; Manfred Rohde; Michael Hogardt; Klaus Pfeffer; Holger Rüssmann; Wolf-Dietrich Hardt
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

7.  Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets.

Authors:  Chantal Beumer; Marty Wulferink; Willem Raaben; Daniëlle Fiechter; Ruud Brands; Willem Seinen
Journal:  J Pharmacol Exp Ther       Date:  2003-09-11       Impact factor: 4.030

8.  Mucin degradation mechanisms by distinct Pseudomonas aeruginosa isolates in vitro.

Authors:  Lina Panayiota Aristoteli; Mark D P Willcox
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

9.  Epithelial inflammation response induced by Shigella flexneri depends on mucin gene expression.

Authors:  Sophie Nutten; Philippe Sansonetti; Guillemette Huet; Caroline Bourdon-Bisiaux; Bertrand Meresse; Jean-Frédéric Colombel; Pierre Desreumaux
Journal:  Microbes Infect       Date:  2002-09       Impact factor: 2.700

10.  Two glycosylation alterations of mouse intestinal mucins due to infection caused by the parasite Nippostrongylus brasiliensis.

Authors:  Jessica M Holmén; Fredrik J Olson; Hasse Karlsson; Gunnar C Hansson
Journal:  Glycoconj J       Date:  2002-01       Impact factor: 2.916

View more
  70 in total

1.  Impact of Eimeria tenella Coinfection on Campylobacter jejuni Colonization of the Chicken.

Authors:  Sarah E Macdonald; Pauline M van Diemen; Henny Martineau; Mark P Stevens; Fiona M Tomley; Richard A Stabler; Damer P Blake
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

Review 2.  Vaccination against Salmonella Infection: the Mucosal Way.

Authors:  Rémi Gayet; Gilles Bioley; Nicolas Rochereau; Stéphane Paul; Blaise Corthésy
Journal:  Microbiol Mol Biol Rev       Date:  2017-06-14       Impact factor: 11.056

3.  Intestinal epithelium-specific MyD88 signaling impacts host susceptibility to infectious colitis by promoting protective goblet cell and antimicrobial responses.

Authors:  Ganive Bhinder; Martin Stahl; Ho Pan Sham; Shauna M Crowley; Vijay Morampudi; Udit Dalwadi; Caixia Ma; Kevan Jacobson; Bruce A Vallance
Journal:  Infect Immun       Date:  2014-06-23       Impact factor: 3.441

4.  Antimicrobial peptides and the enteric mucus layer act in concert to protect the intestinal mucosa.

Authors:  Aline Dupont; Lena Heinbockel; Klaus Brandenburg; Mathias W Hornef
Journal:  Gut Microbes       Date:  2014

Review 5.  LncRNA: A Potential Research Direction in Intestinal Barrier Function.

Authors:  Zhi-Feng Jiang; Lin Zhang
Journal:  Dig Dis Sci       Date:  2020-06-26       Impact factor: 3.199

Review 6.  Gut-liver axis at the frontier of host-microbial interactions.

Authors:  Katharina Brandl; Vipin Kumar; Lars Eckmann
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-02-23       Impact factor: 4.052

7.  Initial Gut Microbial Composition as a Key Factor Driving Host Response to Antibiotic Treatment, as Exemplified by the Presence or Absence of Commensal Escherichia coli.

Authors:  Tingting Ju; Yasmeen Shoblak; Yanhua Gao; Kaiyuan Yang; Janelle Fouhse; B Brett Finlay; Yee Wing So; Paul Stothard; Benjamin P Willing
Journal:  Appl Environ Microbiol       Date:  2017-08-17       Impact factor: 4.792

Review 8.  Microbiota-mediated inflammation and antimicrobial defense in the intestine.

Authors:  Silvia Caballero; Eric G Pamer
Journal:  Annu Rev Immunol       Date:  2015-01-02       Impact factor: 28.527

9.  The levels of Brachyspira hyodysenteriae binding to porcine colonic mucins differ between individuals, and binding is increased to mucins from infected pigs with de novo MUC5AC synthesis.

Authors:  Macarena P Quintana-Hayashi; Maxime Mahu; Nele De Pauw; Filip Boyen; Frank Pasmans; An Martel; Pushpa Premaratne; Harvey R Fernandez; Omid Teymournejad; Lien Vande Maele; Freddy Haesebrouck; Sara K Lindén
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

Review 10.  Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease.

Authors:  Joseph M Pickard; Melody Y Zeng; Roberta Caruso; Gabriel Núñez
Journal:  Immunol Rev       Date:  2017-09       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.